HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors.

Abstract
High-dose thiotepa was given as a single agent at a total dose of 1125 mg/m2 with autologous bone marrow rescue to nine patients with recurrent/refractory/poor risk pediatric malignancies (primitive neuroepithelial tumor (PNET), two; neuroblastoma, one; Wilms' tumor, one; osteosarcoma, one; Ewing's sarcoma one, Hodgkin's disease one, high-grade glioma, two). The response rate in these heavily pretreated patients was 71% (five out of seven evaluable patients) including two complete responses (Wilms', glioma), three partial responses (osteosarcoma, Ewing's sarcoma, Hodgkin's disease), and two with stable disease (PNET, glioma). The median duration of response was 2.5 months. The extramedullary toxicity was acceptable with symptoms mainly of skin and gastrointestinal tract. The data indicate that high-dose thiotepa is effective in several types of recurrent pediatric solid tumors, and merits further evaluation in combination regimens.
AuthorsU M Saarinen, L Hovi, A Mäkipernaa, P Riikonen
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 8 Issue 5 Pg. 369-76 (Nov 1991) ISSN: 0268-3369 [Print] England
PMID1768972 (Publication Type: Journal Article)
Chemical References
  • Thiotepa
Topics
  • Adolescent
  • Bone Marrow Transplantation (adverse effects)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Evaluation Studies as Topic
  • Female
  • Graft Survival
  • Humans
  • Infections (etiology)
  • Male
  • Neoplasms (drug therapy, surgery)
  • Skin (drug effects)
  • Thiotepa (administration & dosage, adverse effects)
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: